FFA
PACB icon

Fairfield Financial Advisors’s Pacific Biosciences PACB Stock Holding History

Fairfield Financial Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$195 – 316
2023
Q1 		$195 Hold
20
– – ﹤0.01% 314
2022
Q4 		$164 Hold
20
– – ﹤0.01% 306
2022
Q3 		$116 Hold
20
– – ﹤0.01% 318
2022
Q2 		$88 Hold
20
– – ﹤0.01% 303
2022
Q1 		$182 Buy
+20
New +$230 ﹤0.01% 304

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fairfield Financial Advisors's PACB Position: Q2 2023 in Review

Fairfield Financial Advisors sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 20 shares — an estimated $195 sold.

Fairfield Financial Advisors first reported a position in PACB in Q1 2022 and held it in 5 quarters. The position peaked at $195 in Q1 2023. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Fairfield Financial Advisors reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Fairfield Financial Advisors sold 20 Pacific Biosciences shares in Q2 2023, an estimated $195.
  • Fairfield Financial Advisors first reported a position in Pacific Biosciences in Q1 2022 and held it in 5 quarters.
  • Fairfield Financial Advisors's Pacific Biosciences position peaked at $195 in Q1 2023.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Fairfield Financial Advisors's 13F filing for Q2 2023, filed 4 Nov 2024.